SCHEDULE: Stonepine Capital Boosts Curis Stake to 9.9%

Stonepine Capital Management and its affiliates reported a 9.9% beneficial ownership stake in Curis Inc., totaling 4,025,992 common shares.

Summary

• Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico jointly reported beneficial ownership of 4,025,992 shares of Curis Inc. Common Stock.
• This represents a 9.9% stake in the company's outstanding common stock.
• The ownership includes 3,704,462 shares of Common Stock and warrants to acquire 10,000,002 shares, which are subject to a 9.99% beneficial ownership limitation.
• The percentage is calculated based on 39,978,693 shares of Common Stock outstanding as of March 20, 2026, as reported in Curis Inc.'s Form 10-K for the fiscal year ended December 31, 2025.
• The reporting persons disclaim that the securities were acquired or are held for the purpose of changing or influencing control of Curis Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional investor taking a substantial stake often signals confidence in the company's long-term value, even if the filing is passive.

Positives

• A significant institutional investor, Stonepine Capital, has taken a substantial 9.9% stake in Curis Inc., indicating confidence in the company's future prospects.
• The investment includes both direct common stock holdings and warrants, suggesting a long-term bullish outlook with potential for increased ownership.

Risks

• The warrants to acquire 10,000,002 shares are subject to a 9.99% beneficial ownership limitation, which could cap Stonepine's immediate ability to increase its voting power beyond the reported 9.9% without further disclosures or waivers.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Curis Inc. It is a disclosure of beneficial ownership by an institutional investor.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from Curis Inc. management. It includes certifications from Jon M. Plexico on behalf of Stonepine Capital entities stating the securities were not acquired for control purposes.

Industry Context

StockSavvy.ai notes that significant institutional investment in a biotechnology company like Curis Inc. can signal market confidence in its drug pipeline or strategic direction. Such filings often precede increased scrutiny or potential activist interest, though Stonepine Capital explicitly disclaims intent to influence control.

Comparison to Industry Standards

• This is a Schedule 13G filing, which is a standard disclosure for passive institutional investors acquiring more than 5% of a company's stock.
• The 9.9% stake is a substantial position, comparable to other significant institutional holdings seen in small to mid-cap biotech firms where a few large investors can hold considerable influence.
• For example, similar stakes are often seen in companies like Mirati Therapeutics or Blueprint Medicines, where specialized healthcare funds take significant positions based on clinical trial progress or market potential.

Stakeholder Impact

• Shareholders: Increased institutional ownership could be viewed positively, potentially stabilizing the stock or signaling validation of the company's strategy.
• Management: Awareness of a significant shareholder may influence strategic decisions, though Stonepine Capital disclaims intent to influence control.

Next Steps

• The filing does not mention any specific future actions or milestones for Curis Inc. or the reporting persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a substantial stake in Curis Inc., which can be a positive signal. However, as a Schedule 13G, it's a passive filing and does not provide new operational or financial performance data. While the increased institutional interest is noteworthy, without further fundamental analysis of Curis Inc.'s business, drug pipeline, and financial health, a 'hold' recommendation is appropriate for existing investors, and potential new investors should conduct further due diligence.

Keywords

Curis Inc., Stonepine Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, Biotechnology, Pharmaceuticals